• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Ann Med . Impact of COVID-19 on chronic kidney disease progression in non-dialysis patients: a retrospective cohort study in Palestine

tetano

Editor, Senior Moderator
Ann Med


. 2025 Dec;57(1):2479236.
doi: 10.1080/07853890.2025.2479236. Epub 2025 Mar 18. Impact of COVID-19 on chronic kidney disease progression in non-dialysis patients: a retrospective cohort study in Palestine

Fadi Basha[SUP] 1 [/SUP], Yazan Dumaidi[SUP] 1 [/SUP], Masa Sabbobeh[SUP] 1 [/SUP], Hamzeh Almasri[SUP] 2 [/SUP], Ahmad Rjoub[SUP] 1 [/SUP], Zakaria Hamdan[SUP] 3 [/SUP], Zaher Nazzal[SUP] 4 [/SUP]



Affiliations
Abstract

Background: This study aims to evaluate the impact of COVID-19 on the progression of CKD in non-dialysis patients and its relation to clinical outcomes in Palestine.
Materials and methods: We conducted a retrospective cohort study that followed non-dialysis CKD patients receiving treatment at outpatient clinics in governmental hospitals. Out of the 248 CKD patients who met the inclusion criteria, 98 were diagnosed with COVID-19 between March 2020 and March 2022. We collected data at three distinct time intervals, both prior to and after their COVID-19 infection. We examined the decline in eGFR and gathered demographic information, hospitalization, and mortality rates. The drop in eGFR was recorded 15 months from baseline.
Results: The mean age of the patients was 55 years, with 55.6% being male. Patients diagnosed with COVID-19 faced a significantly higher risk of rapid deterioration in eGFR, with a 3.7-fold increase compared to those without COVID-19 (ap-value: <0.001; aOR: 3.7; 95% CI: 2.1-6.3). Additionally, COVID-19 patients had 4.4 times higher mortality rates (ap-value: 0.005; aOR: 4.4; 95% CI: 1.6-12.4), 13.3 times higher rates of dialysis initiation within 15 months post-baseline (ap-value: <0.001; aOR: 13.3; 95% CI: 6.1-28.7), and 3.5 times higher rates of hospital admissions (ap-value: <0.001; aOR: 3.5; 95% CI: 1.8-6.7) compared to the COVID-19 negative group.
Conclusion: CKD patients who contract COVID-19 experience a more rapid decline in kidney function, leading to worse health outcomes, including increased mortality rates, a greater need for dialysis, and higher hospitalization rates.

Keywords: COVID-19; Chronic kidney disease; eGFR; non-dialytic patients.

 
Back
Top Bottom